Related Experiment Videos
Folate-mediated targeting: from diagnostics to drug and gene delivery
1Endocyte Pharmaceuticals, 1205 Kent Avenue, 47906, West Lafayette, IN, USA
Abstract:
The covalent attachment of the vitamin folic acid to almost any molecule yields a conjugate that can be endocytosed into folate receptor-bearing cells. Because folate receptors are significantly overexpressed in the majority of human cancers, this methodology is currently being investigated for the selective delivery of imaging and therapeutic agents to tumor tissue. Phase I and II clinical studies for the first folate-containing imaging agent were initiated in 1999, and clinical trials of folate-targeted therapeutic agents should soon follow. This review will summarize folate-mediated drug delivery and highlight those techniques undergoing active preclinical or clinical investigation.
Insights
Folic acid conjugates target cancer cells by exploiting overexpressed folate receptors. This approach enables selective delivery of imaging and therapeutic agents, with clinical trials underway for enhanced cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Bioconjugation Chemistry
Background:
- Folate receptors are overexpressed in many human cancers.
- Folic acid conjugation allows targeted cellular uptake via endocytosis.
- This presents a strategy for cancer-specific drug and imaging agent delivery.
Purpose of the Study:
- To review folate-mediated drug delivery strategies.
- To highlight current preclinical and clinical investigations.
- To discuss the potential of folate conjugates in cancer therapy and diagnostics.
Main Methods:
- Covalent attachment of folic acid to various molecules.
- Utilizing folate receptor-mediated endocytosis for cellular targeting.
- Reviewing existing clinical and preclinical data on folate conjugates.
Main Results:
- Folate conjugates demonstrate selective uptake in folate receptor-positive cells.
- Early clinical studies for folate-based imaging agents have commenced.
- Folate-targeted therapeutics are progressing towards clinical trials.
Conclusions:
- Folate-mediated drug delivery is a promising strategy for cancer treatment.
- Targeted delivery enhances efficacy and reduces systemic toxicity.
- Ongoing research and clinical trials are validating this approach for oncology.